Wall Street brokerages expect REDHILL BIOPHAR/S (NASDAQ:RDHL) to announce earnings per share (EPS) of ($0.39) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for REDHILL BIOPHAR/S’s earnings, with estimates ranging from ($0.40) to ($0.38). REDHILL BIOPHAR/S reported earnings of ($0.50) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 22%. The business is expected to report its next earnings results on Thursday, February 28th.

According to Zacks, analysts expect that REDHILL BIOPHAR/S will report full year earnings of ($1.76) per share for the current fiscal year, with EPS estimates ranging from ($1.80) to ($1.67). For the next financial year, analysts forecast that the firm will post earnings of ($1.41) per share, with EPS estimates ranging from ($1.80) to ($1.10). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover REDHILL BIOPHAR/S.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its quarterly earnings data on Tuesday, November 13th. The biotechnology company reported ($0.40) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.40). The firm had revenue of $2.21 million for the quarter, compared to analyst estimates of $2.54 million. REDHILL BIOPHAR/S had a negative return on equity of 112.99% and a negative net margin of 461.55%.

A number of research analysts have commented on RDHL shares. Zacks Investment Research lowered REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a research report on Tuesday, September 4th. ValuEngine upgraded REDHILL BIOPHAR/S from a “sell” rating to a “hold” rating in a research report on Wednesday, October 3rd. Finally, HC Wainwright set a $36.00 price objective on REDHILL BIOPHAR/S and gave the company a “buy” rating in a research report on Tuesday, October 23rd. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $20.81.

A number of institutional investors and hedge funds have recently made changes to their positions in RDHL. ARK Investment Management LLC boosted its position in shares of REDHILL BIOPHAR/S by 8.6% in the 2nd quarter. ARK Investment Management LLC now owns 112,648 shares of the biotechnology company’s stock worth $961,000 after purchasing an additional 8,894 shares during the last quarter. 683 Capital Management LLC boosted its position in shares of REDHILL BIOPHAR/S by 22.8% in the 2nd quarter. 683 Capital Management LLC now owns 2,042,654 shares of the biotechnology company’s stock worth $17,424,000 after purchasing an additional 378,751 shares during the last quarter. Creative Planning boosted its position in shares of REDHILL BIOPHAR/S by 16.1% in the 3rd quarter. Creative Planning now owns 162,950 shares of the biotechnology company’s stock worth $1,439,000 after purchasing an additional 22,561 shares during the last quarter. Clear Harbor Asset Management LLC bought a new position in shares of REDHILL BIOPHAR/S in the 3rd quarter worth $323,000. Finally, JPMorgan Chase & Co. boosted its position in shares of REDHILL BIOPHAR/S by 61.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 28,102 shares during the last quarter. Hedge funds and other institutional investors own 32.27% of the company’s stock.

RDHL traded up $0.02 during mid-day trading on Monday, reaching $7.05. The stock had a trading volume of 491,989 shares, compared to its average volume of 138,266. The firm has a market capitalization of $149.55 million, a price-to-earnings ratio of -2.71 and a beta of 0.88. REDHILL BIOPHAR/S has a 52 week low of $4.40 and a 52 week high of $11.49.

About REDHILL BIOPHAR/S

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.

Further Reading: Institutional Investors

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.